Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast: Click hereDate: Tuesday, November 8, 2022 – 4:30 p.m. ETDomestic: 888-437-3179International: 862-298-0702Conference ID: 13733692

A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts

Vaxart Media Relations: Investor Relations:
Mark Herr Andrew Blazier
Vaxart, Inc. FINN Partners
mherr@vaxart.com IR@Vaxart.com
(203) 517-8957 (646) 871-8486
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Vaxart Charts.
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Vaxart Charts.